Davita (DVA) Given Coverage Optimism Score of 0.20

News headlines about Davita (NYSE:DVA) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Davita earned a news impact score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1999200177723 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have effected Accern’s analysis:

Davita (NYSE:DVA) traded up $0.02 on Tuesday, reaching $79.15. The company had a trading volume of 1,244,610 shares, compared to its average volume of 1,667,520. The company has a market cap of $14,510.00, a P/E ratio of 30.33 and a beta of 0.96. Davita has a twelve month low of $52.51 and a twelve month high of $80.71. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35.

Davita (NYSE:DVA) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). The firm had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. Davita had a net margin of 3.40% and a return on equity of 13.31%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.95 earnings per share. sell-side analysts predict that Davita will post 3.42 EPS for the current year.

Davita announced that its board has authorized a share repurchase plan on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Several analysts recently issued reports on the company. Bank of America restated a “buy” rating and issued a $92.00 price target (up from $85.00) on shares of Davita in a research note on Thursday, January 11th. Robert W. Baird restated a “buy” rating and issued a $95.00 price target (up from $82.00) on shares of Davita in a research note on Friday. Wolfe Research upgraded Davita from a “market perform” rating to an “outperform” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. boosted their price target on Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 7th. Finally, SunTrust Banks set a $70.00 price target on Davita and gave the company a “hold” rating in a research note on Thursday, December 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $78.22.

In other news, Chairman Kent J. Thiry sold 81,800 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $68.04, for a total transaction of $5,565,672.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Charles Berg sold 7,048 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now owns 5,359 shares of the company’s stock, valued at $371,057.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,937 shares of company stock valued at $8,028,379. Corporate insiders own 2.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Davita (DVA) Given Coverage Optimism Score of 0.20” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/16/davita-dva-given-coverage-optimism-score-of-0-20.html.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Insider Buying and Selling by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply